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Abstract
Background: The cohort multiple randomised controlled trial (cmRCT) design provides an opportunity to
incorporate the benefits of randomisation within clinical practice; thus reducing costs, integrating electronic
healthcare records, and improving external validity. This study aims to address a key concern of the cmRCT design:
refusal to treatment is only present in the intervention arm, and this may lead to bias and reduce statistical power.
Methods: We used simulation studies to assess the effect of this refusal, both random and related to event risk, on
bias of the effect estimator and statistical power. A series of simulations were undertaken that represent a cmRCT
trial with time-to-event endpoint. Intention-to-treat (ITT), per protocol (PP), and instrumental variable (IV) analysis
methods, two stage predictor substitution and two stage residual inclusion, were compared for various refusal
scenarios.
Results: We found the IV methods provide a less biased estimator for the causal effect when refusal is present in
the intervention arm, with the two stage residual inclusion method performing best with regards to minimum bias
and sufficient power. We demonstrate that sample sizes should be adapted based on expected and actual refusal
rates in order to be sufficiently powered for IV analysis.
Conclusion: We recommend running both an IV and ITT analyses in an individually randomised cmRCT as it is
expected that the effect size of interest, or the effect we would observe in clinical practice, would lie somewhere
between that estimated with ITT and IV analyses. The optimum (in terms of bias and power) instrumental variable
method was the two stage residual inclusion method. We recommend using adaptive power calculations, updating
them as refusal rates are collected in the trial recruitment phase in order to be sufficiently powered for IV analysis.
Keywords: Trials within cohorts, Cohort multiple randomised controlled trial, Pragmatic trial, Instrumental variable
Background
Clinical trials are facing increasing costs, complexities,
and poor accrual, all threatening the viability of the
current clinical trial model [1]. There is a vital need for
trial designs that promote increased external validity and
cost efficiency so we can continue to deliver medical
benefits to patients [2]. To this end, there have been fre-
quent calls for more pragmatic generalizable trials [3, 4].
A simplification of trial eligibility criteria and integration
of routine electronic health records to monitor trial out-
comes should play a key role in the development of prag-
matic trials [1, 3]. The cohort multiple randomised
controlled trial design [5] (cmRCT, also referred to as trial
within cohorts design) is a simple and efficient pragmatic
trial design that could address some of the issues dis-
cussed. In a cmRCT design we identify a large observa-
tional cohort, and at the outset consent is obtained from
participants both for random allocation to interventions
in the future, and to use their medical records data. For a
given intervention, eligible patients are identified from the
cohort and a random selection are offered the interven-
tion. The remaining eligible patients are assigned to the
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control group and are not formally recruited into the trial,
thus addressing some of the issues with trial accrual.
The cmRCT design offers several advantages. First, the
use of a large observational cohort enables multiple trials
over time and as patients all come from the same cohort
comparability of these trials is improved [5]. Second, elec-
tronic healthcare records reduce recruitment and follow-
up costs [6], making it possible to have a large control
arm requiring minimal additional costs for follow-up.
Third, both the intervention and standard of care are
delivered at the point of care enabling us to assess the
effectiveness of both interventions in real life conditions
as opposed to under strict trial conditions.
A cmRCT design has several limitations [5, 7]. The
use of routine data will require a mix of skill sets from
both clinical trial and observational research, possibly in-
creasing costs. Loss to follow-up may be a significant issue
if linkage of routine data linkage is not possible. The com-
parator is standard of care, this may contain a variety of
treatments with some self-selected by the patient so is
somewhat an unknown. The feasibility of standardised
outcome measures may also be challenging when using
routine data. Blinding of participants in the intervention is
not possible in the cmRCT design. If the cohort of eligible
patients is too small in a cmRCT and refusal is high, it is
not possible to keep recruiting until the required power is
achieved as this will start oversampling from the control
arm leading to a less powerful trial than the standard two
arm. A notable limitation is that only patients randomly
selected to receive the experimental intervention have the
option to refuse the allocated treatment. This refusal may
differ from the refusal we see in routine care due to the
experimental nature of the study. Refusal can potentially
lead to bias in the treatment effect estimate and loss of
power. Though the cmRCT design is a recent proposal, its
uptake has been fairly broad in application [8–12] and on-
going cmRCTs have scarcely considered the matter of re-
fusal. Where mention of intended analysis methods were
available, intention-to-treat was always used. Only one
trial made explicit assumptions about the proportions of
refusers in the intervention arm, assuming a 20% refusal
rate and planned to use complier average causal effect
(CACE) [13] analysis if refusal in the intervention arm was
large [10], another noting CACE analysis as a secondary
analysis method [9]. CACE analysis provides an unbiased
treatment effect estimate for individuals who comply with
the protocol, unlike intention-to-treat or per-protocol;
however, there is generally a loss of power.
The effects of non-uptake of the experimental inter-
vention in cmRCT are unclear. In this study, we under-
took a simulation study to test the validity of the
cmRCT design in the presence of treatment refusal. The
objectives were to assess the bias present in the cmRCT
design due to differential refusals and any loss in
statistical power. We identify scenarios where cmRCT
are viable designs for point-of-care trials and suggest al-
ternate statistical methods, such as instrumental variable
analysis, which can be used to reduce bias.
Randomised trials are often divided into two types, in-
dividually randomised – individuals randomized to trial
arm - or cluster randomized trials – clusters (groups of
individuals or communities) randomized to trial arm. In
certain scenarios cluster trials can be more appropriate
(for instance when we anticipate contamination between
trial arms), they can also improve accrual and reduce
costs. However, cluster trials require specific design, stat-
istical analysis and interpretation and are not always
beneficial. In cluster trials we generally anticipate an
inflation of the variance due to correlation among indi-
viduals in the same cluster, therefore, they require larger
sample sizes than individually randomized trials de-
signed to answer the same research question (if an indi-
vidually randomized trial is possible) and more complex
analysis to account for the correlation of outcomes
within a cluster. This paper focusses on individually ran-
domised cmRCTs, representative of the randomization
used in the original cmRCT design and existing
cmRCT studies [5]. The case of a cluster cmRCT has
been investigated by Pate et al. [14]; differing effects of
the refusal on power were found between the cluster
and individual trial scenarios. As sample sizes for trials
using the cmRCT design will be limited to the size of
the cohort, the benefits and requirements for cluster level
randomization should be considered with caution.
Methods
Data were simulated to represent hypothetical trials
using a cmRCT design with randomisation of individual
patients. The cohort of patients was those receiving
standard of care for a particular condition. The trial
assessed the effect of an intervention compared with
standard of care, with an outcome of time to cardiovas-
cular disease (CVD) event and effect estimate the hazard
ratio. The simulations replicated a cmRCT study which
assessed the effect of an intervention compared with
standard of care for patients at risk of cardiovascular dis-
ease (CVD) and eligible for lipid lowering drugs [14].
The outcome of interest was the time to CVD event. We
define treatment effect, the parameter of interest, as the
complier average causal effect (defined counterfactually)
of the treatment (taken per protocol) on (hazard of ) out-
come. Refusal of the intervention and correlation be-
tween this refusal and baseline risk were varied to create
different trial scenarios. It was assumed that the under-
lying risk for the outcome of interest varied between pa-
tients. We used bias (error in the estimation of the causal
treatment effect), statistical power, and standard error of
the mean treatment effect as measures of performance.
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Analysis methods
We assessed the bias and variance of effect estimators
associated with different analysis methods when treat-
ment refusal was present in the intervention arm of a
cmRCT study. The methods included: intention-to-treat
(ITT), per protocol (PP) and two instrumental variable
(IV) analysis techniques. Current trial guidance recom-
mends ITT analysis [15]; however, this dilutes the treat-
ment effect in the presence of refusal which may result
in biased estimates of the causal effect of a treatment,
according to our specific definition of treatment effect
above [16]. PP analysis excludes people from the study
who do not follow protocol, generally yielding biased re-
sults as adherence to protocols is often non-random
[17]. IV analysis estimates the effect of exposure (X)
on the outcome (Y), accounting for all unmeasured
confounding. The IV technique is a two stage
analysis; the first stage assesses how an unbiased in-
strument (randomisation, Z) predicts the exposure
(treatment received, X); the second stage uses this in-
formation to understand how the exposure predicts
the outcome (Y). The performance measures used to
assess the four methods were the bias of the estimate
of treatment effect, statistical power and standard
error.
Figure 1 represents the causal relationships required
for an IV analysis in a trial. The three main assumptions
for the validity of an instrumental variable are: it is
strongly associated with exposure, it has no effect on the
outcome other than through the exposure, and it is in-
dependent of confounders of the exposure outcome rela-
tionship [18]. In an RCT randomisation (Z) meets these
assumptions; however, the strength of association with
exposure depends upon the non-compliance rates. The
performance of two IV approaches were compared, the
two stage predictor substitution (2SPS) method and the
two stage residual inclusion (2SRI) method [19, 20]. The
2SPS method is a straightforward two stage regression
approach. First, regress IV on exposure, Z on X, and let
X^ ¼ E XjZð Þ. In the second stage fit a model for the out-
come, Y, including X^ as a covariate. The coefficient of X^
from the second stage model is the IV estimated treat-
ment effect of interest. Similarly, in the first stage of the
2SRI method regress Z on X, and then calculate the
residual term R = X − E(X|Z). In the second stage, fit a
model for the outcome, Y, including both treatment re-
ceived, X, and residuals, R, as covariates in the model.
The coefficient of X in the second stage model is the IV
estimated treatment effect.
Simulation overview
Simulations were undertaken using statistical software
SAS version 9.4 (SAS Institute Inc, Cary, NC) and plots
in R version 3.1.2 followed standard guidelines [21]. Sim-
ulations replicated a cmRCT study evaluating the effect
of an intervention compared with standard of care for
patients at risk of CVD [14]. The outcome was time
until CVD event, which is of direct importance to the
patient, as opposed to some surrogate endpoints [22].
Simulated patient characteristics included: baseline risk
of a CVD event (for example, acute myocardial infarc-
tion/stroke (fatal or non-fatal) and death attributable to
CVD), time to non-CVD mortality, and probability of re-
fusing the intervention. If non-CVD mortality event oc-
curred before the CVD they were treated as censored.
Clinician probability of refusing to offer the intervention
was also simulated. The data generating models for time
to both CVD event and mortality were Weibull distribu-
tions, with distribution parameters chosen to give a cor-
relation of 0.25 between CVD and mortality to represent
informative censoring. The distribution parameters were
chosen so the mean and standard deviation of the ten
year CVD risk were representative of the population eli-
gible for lipid lowering drugs, 21.1 and 8.7% respectively
[14]. Refusal was only present in the intervention arm.
We assume the treatment has no effect on the compet-
ing risk of death from other causes than CVD event.
We used Weibull baseline hazard functions for all in-
dividuals for time until CVD event, Tc, and time until
mortality, Tm. Individual risks were created by incorpor-
ating individual random effects to the Weibull baseline
hazard function. Given that the shape parameter of a
Weibull distribution is fixed, then the proportional
hazards assumption holds. The intervention effect used
was an average reduction in ten year CVD risk by 25%.
The trial follow-up used, Tmax, was three years as a
plausible follow-up period in a survival trial. All simula-
tion variables are presented in Table 1.
Fig. 1 Directed acrylic graph representing randomised trial with treatment refusal
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Different trial scenarios were generated through
varying both the average refusal probability and the
correlation of refusal with individual risk. The average
patient refusal probability, p, and average clinician re-
fusal probability, q, took values of 0.1, 0.2, or, 0.3. Dif-
ferent correlation scenarios were created by defining
an upper limit (UL) and lower limit (LL) that all indi-
viduals’ refusal probability lies between and assigning
refusal probabilities equally spaced between these
values. Patients were ordered (ascending or descend-
ing) by their individual random effect εi. Correlation
between CVD risk and refusal probability took values
defined as zero, low, medium, or high using upper and
lower limits for individual refusal probabilities LL;ULð Þ∈
p; pð Þ; 2p3 ; 4p3
 
; p3 ;
5p
3
 
; 0; 2pð Þ . For each scenario we simu-
lated 1000 realisations of the trial data.
Sample sizes were calculated under two different re-
cruitment methods: recruitment without refusal assumed
no refusal and recruitment with refusal used the expected
refusal rate in the sample size calculation (this assumes re-
fusal is non-informative for the sample size calculation –
not for estimating effects). Both recruitment methods
were used for all simulated trial scenarios. We calculated
the required sample size using bootstrap methods [23], an
unequal randomisation method of 4:1 standard of care:in-
tervention, 0.80 statistical power, a type I error rate of 0.05
and a minimum treatment effect tested of an average re-
duction in ten year CVD risk by 25% (taken as the mini-
mum clinically important effect). If a trial budget is fixed
but there is no limitation to the total sample size then an
increased statistical power can be obtained by sampling
more patients from the control arm [24], hence the un-
equal randomisation ratio. Cox proportional hazard sur-
vival models were used to provide effect estimates under
each analysis method.
Simulation steps
We simulated 1000 trials each with size Nobs, i = 1,…,Nobs
for each different combination of parameters. For j = 1,…,
1000 the following procedure was undertaken to simulate
hypothetical time to event trial data:
1) Individuals risks: Generate individual random effects,
εi s for each patient, i = 1,…,Nobs.
2) Refusal probabilities: Order patients by their
individual random effect, εi. Generate refusals
either randomly or related to underlying CVD
risk by relating them with individual random
effect order εi. The probability of a patient
refusing intervention if offered it is pi and the
probability of clinician refusing to offer the
intervention to the patient is qi.
3) Randomisation: Randomise to standard of care
Zi =0, or intervention, Zi =1, on a 4:1 basis.
4) Treatment: Generate the treatment actually
received, Xi =0/1 for standard of care/intervention.
All those in control arm (Zi = 0) receive standard of
care (Xi = 0) and those randomised to intervention
arm (Zi = 1) receive either intervention or standard
of care dependent upon their refusal, Xi = min
{Bernoulli(1 − pi), Bernoulli(1 − qi)}.
5) Hazard rate: Apply intervention effect, β ¼  0:32,
and individual random effects to the Weibull
baseline hazard function to give
h ticð Þ ¼ h0 tcð Þ e βXiþεið Þ; and h timð Þ ¼ h0 tmð Þ e εið Þ:
6) Time to event: Simulate individual time to event Tic
and Tim from corresponding Weibull distributions.
7) Censoring: Generate Ci the censoring indicator Ci
=0/1 if outcome is an observed event/censored. We
observe the continuous outcome Yi =min(Tic, Tim,
Tmax) and the observed trial data is then {Yi, Ci, Zi,
Xi}, a set of censored survival data, treatment
allocations, and treatments received.
8) Analysis: Using ITT, PP, 2SPS, and 2SRI methods
fit a Cox proportional hazards model to estimate
Table 1 Variables included in the simulation study, generating
models, and notation
Variable description Generating models and notation
Number of simulated data sets Nsim
Sample size each data set Nobs
Treatment allocated Zi = 0/1 for standard of care/
intervention
Treatment received Xi = 0/1 for standard of care/
intervention
Baseline hazard function for
time until CVD event
h0 tcð Þ ¼ γcλγcc tcγc−1 ; λc ¼ 36; γc ¼ 1:2
Baseline hazard function for
time mortality
h0 tmð Þ ¼ γmλγmm ; λm ¼ 55; γc ¼ 1:2
Individual random effects εi ~ N(0, σ2), σ = 0.7
Intervention effect β = − 0.32
Individual hazard function for
time until CVD event
h ticð Þ ¼ h0 tcð Þ e βXiþεið Þ
Individual hazard function for
time until mortality
h timð Þ ¼ h0 tmð Þ e εið Þ
Probability of a patient refusing
intervention if offered and
average patient refusal
pi ; p ¼ Σ ipi=Nobs
Probability of clinician refusing
to offer the intervention to the
patient and average clinician
refusal
qi ; q ¼ Σ iqi=Nobs
Trial follow-up time in years Tmax = 3
Censoring indicator Ci = I(Tic≥min(Tim, Tmax ))
Observed outcome Yi =min(Tic, Tim, Tmax)
Observed trial data {Yi, Ci, Zi, Xi}
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the effect estimate β^j and the corresponding
p-value, sj for each of the four different
estimators.
The same set of simulated data sets were used to com-
pare different methods for the same scenario; however,
for each scenario a different set of data sets was gener-
ated [21]. This enables differences between methods to
be detected. The mean effect estimate β ¼
X
j
β^j=1000,
relative bias β−β
 
=β , and statistical power Ij(pj < 0.05)/
1000 were calculated for each scenario where j = 1,…,
1000. The empirical standard error of the mean effect
estimate, β; over all simulations was calculated as S:E:
β
  ¼ S:D: β^j
 
=1000.
Results
Figure 2 shows the influences of refusal on the causal ef-
fect estimate of the treatment (taken per protocol) on
hazard of outcome and power (using recruitment with-
out refusal). This was done for a positive correlation be-
tween refusal probability and underlying risk for the
outcome. PP increasingly overestimates the effect esti-
mate as correlation strengthens, refusal probabilities of
0.1 correlated to risk led to bias of between 3.3 and
12.8%; the corresponding power increased. ITT esti-
mates were biased; average refusal probabilities of 0.2
underestimated the treatment effect by between 21.5
and 29.0%. As the correlation between refusal and risk
strengthened the ITT estimate underestimated the effect
with increasing magnitude. Both IV methods were less
biased than PP or ITT estimates in all scenarios in Fig. 2.
An average refusal of 0.2 and high correlation resulted
in bias of −11.2% with 2SPS and 8.1% with 2SRI, com-
pared to −29.0% with PP and 32.3% with ITT. The 2SRI
method provided the most accurate effect estimate in all
scenarios when there was correlation between refusal
and risk. The IV and ITT analyses resulted in a lower
power than the expected 0.80, the power of 2SRI fluctu-
ated between a 0.65 and 0.70. Statistical power of both
Fig. 2 Percentage bias (top) and power (bottom) against correlation patient risk and refusal probability using recruitment without refusal and
positive correlation between refusal and risk: both plots are paneled by the refusal probabilities and present results for all four analysis methods.
Black reference lines represent empirical power and zero bias
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2SPS and ITT were equal and generally decreased as re-
fusal and correlations increased.
The bias of the effect estimate and statistical power for
negative correlations between refusal and event risk are
presented in Fig. 3 (using recruitment without refusal). PP
analysis provides underestimated effect estimates, increas-
ing as both refusal and correlation increased; the corre-
sponding power decreased. An average refusal of 0.1
negatively correlated with risk yielded an underestimate of
the effect estimate of between 4.0 and 13.4%, respective
power between 0.78 and 0.68. The ITT analysis again
underestimated the effect estimate, however, here with
decreasing magnitude as correlations strengthened. Both
IV methods followed similar patterns to one another,
overestimation and power generally increasing as correl-
ation strengthened. It is the correlation that most affects
the IV analyses, with bias only reaching greater than 10%
when refusal is 0.3 and correlation is high.
Figure 4 presents the bias of the effect estimate of in-
creasing refusal probabilities and positive correlations
under recruitment with refusal. The biases are consistent
with those under recruitment without refusal, with some
slight variation between the two due to random variation
in the sample. However, the main effect of recruitment
with refusal compared to recruitment without refusal is,
understandably, an increase in statistical power. The 2SRI
analyses resulted in overestimation of the effect by between
0.06 and 13.5% and a power which fluctuated between 0.81
and 0.90. Figure 5 shows the effects on bias and power
when increasing refusal probabilities and strengthening
negative correlations under recruitment with refusal.
Again, the biases follow consistent patterns across both re-
cruitment methods. The ITT and IV analyses were above
the desired statistical power for all scenarios. Of all ap-
proaches the 2SPS performed best in terms of minimum
absolute bias, between −4.9 and 11.7%.
Scenarios with both clinician refusal and patient re-
fusal greater than zero were simulated, with IV methods
again providing the least biased effect estimates. The
bootstrapped standard Fs were calculated to estimate
precision of the effect estimate. For both IV analyses
standard errors were greater than the ITT and PP
Fig. 3 Percentage bias (top) and power (bottom) against correlation patient risk and refusal probability using recruitment without refusal and
negative correlation between refusal and risk: both plots are paneled by the refusal probabilities and present results for all four analysis methods.
Black reference lines represent empirical power and zero bias
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analyses in all scenarios, with little difference between
the standard errors of 2SPS and 2SRI. Considering re-
fusal at only the patient level, as seen in Figs. 2, 3, 4, 5,
recruitment without refusal produced standard errors of
up to 0.11 under ITT analysis and 0.16 under 2SPS and
2SRI analyses. Recruitment with refusal produced con-
sistent standard errors regardless of the correlation of
around 0.08 under ITT analysis and 0.11 under 2SPS
and 2SRI analyses.
Discussion
ITT and PP analysis are equivalent and unbiased with
perfect compliance and IV analysis not necessary. When
refusal is present, the intervention arm comprises both
individuals on intervention and individuals on standard
of care. When this refusal is random and uncorrelated
with event risk, ITT estimates were biased through dilu-
tion bias, bias increasing as refusal rates increased. The
makeup of the event risks of the individuals in the inter-
vention arm depends upon the direction and strength of
the correlation between refusal and event risk thus
inducing bias in the effect estimates. Therefore, the bias
in effect estimate when using ITT analysis is also af-
fected by this correlation between refusal and risk, small
refusal rates resulted in large bias and reduction in
power if correlation was high.
IV analyses provided more accurate effect estimates
when refusal was correlated to event risk. Effect esti-
mates with the smallest absolute bias of all methods
were given by the 2SRI method when correlation be-
tween refusal and risk was positive and the 2SPS method
when correlation between refusal and risk was negative.
However, when 2SPS is less biased, it is only by a small
amount, and when its more biased it is by a large
amount. The 2SPS estimate was also highly effected by
direction of correlation, whereas, 2SRI was relatively
similar irrespective of correlation direction. The stand-
ard errors of IV estimates are larger than ITT or PP due
to the two stage modelling procedure.
Sample size ignoring refusal did not provide the de-
sired power for all methods and all scenarios, except the
PP analysis and positive correlation. The large decrease
Fig. 4 Percentage bias (top) and power (bottom) against correlation patient risk and refusal probability using recruitment with refusal and positive
correlation between refusal and risk: both plots are paneled by the refusal probabilities and present results for all four analysis methods. The black
reference lines represent empirical power and zero bias
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or increase in statistical power under PP analyses as
correlations strengthened was actually indicative of the
large bias present in the effect estimate. Sample size
acknowledging refusal maintained statistical power for
all scenarios when using the 2SRI method and relatively
small bias, only greater than 10% when correlation
between risk and refusal was high.
The simulation results from this study have relevance to
clinical research. Since the development of the cmRCT
design uptake has been increasing in conjunction with the
movement towards developing more pragmatic trial ap-
proaches in order to tackle some of the current challenges
present in the clinical trial model [1]. As new cmRCT co-
horts continue to emerge it is crucial that the design and
analysis of these novel trials remains rigorous. Refusal of
an intervention is pragmatic in the sense that that there
will likely be some level of refusal to treatment in clinical
practice. A certain proportion of the refusal present in a
cmRCT trial will be present in real life, some individuals
would refuse said treatment whether it was offered as part
of a trial or not. However, refusal may be related to the
fact that the intervention is offered as part of a trial. It is
expected that the effect size of interest, or the effect we
would observe in clinical practice, would be somewhere
between that estimated with ITT and IV analyses. All
present cmRCT planned ITT as the main analysis method;
future research would benefit from using actual refusal
rates seen in these trials and thus considering if the refusal
rates used in these simulations are realistic.
It is expected that there will be patients who do not
refuse the intervention, but are noncompliant to some
degree. If the non-compliance present in a trial is also
expected in clinical practice, we believe the intervention
effect estimate can just ignore it, it is realistic of clinical
practice. In a cmRCT, given the passive follow-up of the
control arm, it would not make sense to use any compli-
ance increasing tactics for the intervention arm, and its
likely it would be hard to assess compliance using the
routinely collected data, so lack of compliance should
ideally be treated as part of treatment effect.
Fig. 5 Percentage bias (top) and power (bottom) against correlation patient risk and refusal probability using recruitment with refusal and
negative correlation between refusal and risk: both plots are paneled by the refusal probabilities and present results for all four analysis methods.
The black reference lines represent empirical power and zero bias
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A key limitation of this study is that heterogeneous
treatment effects were not considered and such results
are not generalizable to studies with a heterogeneous
treatment effect. Secondly, adding time dependent co-
variates to the risks may provide a more realistic sce-
nario of how individual risks change over time. Further
work could consider more complex trial scenarios that
may occur in the cmRCT design. For example, when
the new treatment or control treatment is harmful in
terms of non-CVD mortality and how this competing
risk affects the effect estimate and power of the trial
mortality. The effect of multiple trials within the same
cohort, which is an interesting design feature of the
cmRCT, could also be investigated to assess how pos-
sible correlation of control arm affects hypothesis test-
ing and error rates [25]. Due to the use of a cohort in a
cmRCT for recruitment it would also be of interest to
investigate more closely the effect of refusal on power.
For example, considering a trial simulation with a fixed
cohort of size n and different refusal rates, this could
be used to provide an idea of scenarios when it may be
more powerful to do a standard two arm trial than a
cmRCT and thus preferable. As previously discussed if
the cohort of eligible patients in a cmRCT is too small
and the refusal high, there is the risk of oversampling
the control arm leading to a less powerful trial than the
standard two arm RCT.
Conclusion
We have presented simulation results that show both
the biases and statistical power of a cmRCT design are
altered through refusal, particularly non-random refusal.
We recommend a cmRCT design to assess probable re-
fusal rates at the outset as well as the effect estimate,
and to incorporate these into power calculations. We
recommend using adaptive power calculations, updating
them as refusal rates are collected in the trial recruit-
ment phase. The instrumental variable methods provide
a less biased effect estimate when refusal is present in
the intervention arm. On average the 2SRI method pro-
vides effect estimates with the smallest absolute bias of
all methods and sufficient power when using recruit-
ment with refusal. We recommend running both an ITT
and 2SRI analyses as it is expected that the effect size of
interest, or the effect we would observe in clinical prac-
tice, would lie somewhere between those estimated with
ITT and IV analyses. We demonstrate that sample sizes
should be adapted based on expected and actual refusal
rates in order to be sufficiently powered for instrumental
variable analysis.
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